LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund. Oncode Instit.
MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund. Oncode Institute will lead the Oncode-PACT consortium and its .